로딩 중…
지수 로딩 중…
Altimmune, Inc.
ALT· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$3.00+5.63%
2026-08-03
Financials
Valuation Metrics
Altimmune, Inc.'s Market Cap is $583M. At end of 2025 it was $363M. Ranked #2737 of 3,112 in US market (top 88%), #1175 of 1,445 on NASDAQ (top 81%), #217 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 81%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $583M | US#2,737/3,112 Sec#217/269 |
| Revenue | $36000.00 | US#2,972/3,112 Sec#203/269 |
| Net Income | $-91M | US—/3,112 Sec—/269 |
| Total Assets | $336M | US#2,865/3,112 Sec#196/269 |
| Net Assets | $284M | US#2,575/3,112 Sec#163/269 |
| Value | ||
| P/B | 2.05x | US#1,222/3,112 Sec#55/269 |
| P/S | 14229.82x | US#2,962/3,112 Sec#204/269 |
| FCF Yield | -12.28% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -32.07% | US#2,633/3,112 Sec#133/269 |
| ROA | -27.14% | US#2,847/3,112 Sec#152/269 |
| Op. Margin | -269216.67% | US#2,972/3,112 Sec#203/269 |
| Revenue Growth | -100.00% | US#2,948/3,112 Sec#190/269 |
| Financial Health | ||
| Debt Ratio | 18.18% | US#197/3,112 Sec#73/269 |
| Total Debt | $36M | US#2,609/3,112 Sec#160/269 |
| FCF | $-72M | US#2,525/3,112 Sec#128/269 |
| Cash | $98M | US#2,227/3,112 Sec#179/269 |
| Current Ratio | 29.56x | US#82/3,112 Sec#10/269 |
| Performance | ||
| 1Y Return | -16.90% | US#2,499/3,112 Sec#217/269 |
| 1M Return | -5.06% | US#2,245/3,112 Sec#126/269 |
| From 52W High | -53.42% | US#2,843/3,112 Sec#227/269 |
| 1Y MDD | -66.41% | US#2,860/3,112 Sec#239/269 |
| Trading | ||
| Volume | 4,557,462 shares | US#409/3,112 Sec#31/269 |
| Trading Value | $13M | US#2,186/3,112 Sec#171/269 |
| Per Share | ||
| EPS | $-0.88 | US—/3,112 Sec—/269 |
| BPS | $2.24 | US#2,482/3,112 Sec#170/269 |